Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on PlaceboAs a First-in-Class Orexin
Takeda got permission to sell a brand-new medicine called ORZEYFUL that helps people with a sleep disease called narcolepsy type 1 feel much better. This is good news for the company because they're the first to offer this kind of medicine, which could mean more customers and money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.